Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesoblast Stem Cell Therapy in HLHS
NCT03079401Phase 2Unknown
- Sponsor
- Boston Children's Hospital
- Start
- Nov 2017
- Primary completion
- Dec 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of rexlemestrocel-l in hypoplastic left heart syndrome (HLHS), atrioventricular septal defect (AVSD), sponsored by Boston Children's Hospital. Status: unknown.
02
Drugs
rexlemestrocel-l
03
Conditions
hypoplastic left heart syndrome (HLHS)atrioventricular septal defect (AVSD)
Beyond the preview
Go deeper on NCT03079401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03079401.